Education
About Us
Working with TipRanks
Follow Us
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Total Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has a market cap or net worth of HK$15.50B. The enterprise value is HK$6.92B.
Market CapHK$15.50B
Enterprise ValueHK$6.92B
Share Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding220,094,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee2.83M
Profits Per Employee0.00
Employee Count1,926
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is ―. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s PEG ratio is ―.
PE Ratio―
PS Ratio69.73
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H had revenue of 5.45B and earned ― in profits. Earnings per share was -0.53.
Revenue5.45B
Gross Profit1.80B
Operating Income-238.11M
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)-0.53
Cash Flow
In the last 12 months, operating cash flow was 1.51B and capital expenditures 0.00, giving a free cash flow of 1.73B billion.
Operating Cash Flow1.51B
Free Cash Flow1.73B
Free Cash Flow per Share7.84
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays an annual dividend of HK$0.267, resulting in a dividend yield of ―
Dividend Per ShareHK$0.267
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change47.65%
50-Day Moving Average4.38
200-Day Moving Average3.95
Relative Strength Index (RSI)51.23
Average Volume (3m)2.78M
Important Dates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H upcoming earnings date is Apr 25, 2025, TBA Not Confirmed.
Last Earnings DateMar 28, 2025
Next Earnings DateApr 25, 2025
Ex-Dividend DateMay 26, 2025
Financial Position
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has HK$3.08B in cash and marketable securities with ¥4.92B in debt, giving a net cash position of HK$120.58M billion.
Cash & Marketable SecuritiesHK$3.08B
Total Debt¥4.92B
Net CashHK$120.58M
Net Cash Per ShareHK$0.55
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is HK$3.88, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price TargetHK$3.88
Price Target Upside-10.80% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast-4.92%
EPS Growth Forecast―